Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure

Dosagem única de troponina cardíaca T prediz risco adverso na insuficiência cardíaca descompensada

“…Similar findings in previous studies have been observed in outpatients with compensated HF [5][6][7][8][9][10][11][12] and in hospitalized patients with decompensated HF [13][14][15][16][17][18][19][20][21] , with a large variability among the techniques used to measure cardiac troponin, as well as the cutoffs associated with the studied outcomes. The present study did not use seriate measurements of troponin, thus differing from others that used a cutoff identical to ours, such as Sato et al 10 and Del Carlo et al…”

“…As in previous studies 8,11,12,15 , we used a thirdgeneration technique to measure the troponin; however, this technique has a capacity to measure in nanogramas per milliliter (10 -9 g). Wallace et al 28 estimated the prevalence of cardiac TnT in the general population as 0.7% and suggested that the upper limit of the normal range would be 0.01ng/ml.…”

“…Wallace et al 28 estimated the prevalence of cardiac TnT in the general population as 0.7% and suggested that the upper limit of the normal range would be 0.01ng/ml. A cardiac TnT cutoff of 0.02 ng/ml was previously used in the literature in HF studies 15,29 , which corresponds to twice the value observed in normal individuals 28 . According to our results, this cutoff corresponded to the area under the ROC curve of 67.9%, with a sensitivity of 68% and a specificity of 64%, for the prediction of the death outcome, corroborating previously published data 15,29 .…”

Elevated Levels of Both Cardiomyocyte Membrane and Myofibril Damage Markers Predict Adverse Outcomes in Patients With Chronic Heart Failure

“…7 Del Carlo et al reported that CHF patients with detectable TnT within 4 days of admission, but undetectable TnT 7 days later or undetectable TnT on both days, had lower rates of death, rehospitalization or both than patients with detectable TnT on both days or detectable TnT at the time of the second measurement. 25 Sato et al showed that the CE-free rate was significantly lower in patients with continuous TnT detection than in patients in whom TnT became undetectable or was continuously undetectable. 8 Thus, the prognosis in patients with TnT that becomes undetectable is better than that for patients with continuously detectable TnT.…”

Amino-Terminal Pro–Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure

“…Recent studies have demonstrated a prognostic role for troponins and natriuretic peptides in HF (6)(7)(8)(9)(10)(11)(12)(13)(14)(21)(22)(23)(24), yet the optimal mode for applying these markers to assess short-and longer-term mortality risk in acute HF remains unclear. Because the PRIDE study focused on patients without evident ACS at enrollment, it afforded an opportunity to analyze the relationship between natriuretic peptide testing and cTnT in HF without superimposed overt ischemic cardiac events.…”